Jeffrey L Anderson

List of Publications by Year
in descending order

132 papers	13,340 citations	71102 41 h-index	22166 113 g-index
133 all docs	133 docs citations	133 times ranked	21014 citing authors

#	Article	IF	Citations
1	2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk. Circulation, 2014, 129, S49-73.	1.6	2,823
2	Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nature Genetics, 2011, 43, 333-338.	21.4	1,685
3	2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults. Journal of the American College of Cardiology, 2010, 56, e50-e103.	2.8	1,150
4	Acute Myocardial Infarction. New England Journal of Medicine, 2017, 376, 2053-2064.	27.0	761
5	Randomized Trial of Genotype-Guided Versus Standard Warfarin Dosing in Patients Initiating Oral Anticoagulation. Circulation, 2007, 116, 2563-2570.	1.6	660
6	Relation of Vitamin D Deficiency to Cardiovascular Risk Factors, Disease Status, and Incident Events in a General Healthcare Population. American Journal of Cardiology, 2010, 106, 963-968.	1.6	571
7	Infection With Chlamydia pneumoniae Accelerates the Development of Atherosclerosis and Treatment With Azithromycin Prevents It in a Rabbit Model. Circulation, 1998, 97, 633-636.	1.6	488
8	Assessing the Risks Associated with MRI in Patients with a Pacemaker or Defibrillator. New England Journal of Medicine, 2017, 376, 755-764.	27.0	308
9	World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Nature Reviews Cardiology, 2014, 11, 597-606.	13.7	267
10	Oral Flecainide Acetate for the Treatment of Ventricular Arrhythmias. New England Journal of Medicine, 1981, 305, 473-477.	27.0	233
11	A Randomized and Clinical Effectiveness Trial Comparing Two Pharmacogenetic Algorithms and Standard Care for Individualizing Warfarin Dosing (CoumaGen-II). Circulation, 2012, 125, 1997-2005.	1.6	217
12	Randomized Secondary Prevention Trial of Azithromycin in Patients With Coronary Artery Disease. Circulation, 2000, 102, 1755-1760.	1.6	195
13	Health effects of intermittent fasting: hormesis or harm? A systematic review. American Journal of Clinical Nutrition, 2015, 102, 464-470.	4.7	183
14	Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality. American Journal of Cardiology, 2001, 87, 257-261.	1.6	164
15	2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: Executive Summary. Catheterization and Cardiovascular Interventions, 2012, 79, 453-495.	1.7	157
16	HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: the lipoprotein investigators collaborative. European Heart Journal, 2015, 36, 22-30.	2.2	142
17	Effect of fasting glucose levels on mortality rate in patients with and without diabetes mellitus and coronary artery disease undergoing percutaneous coronary intervention. American Heart Journal, 2003, 146, 351-358.	2.7	134
18	Frequency of elevation of C-reactive protein in atrial fibrillation. American Journal of Cardiology, 2004, 94, 1255-1259.	1.6	134

#	ARTICLE	IF	CITATIONS
19	AHA/ACC/HHS Strategies to Enhance Application of Clinical Practice Guidelines in Patients With Cardiovascular Disease and Comorbid Conditions. Circulation, 2014, 130, 1662-1667.	1.6	132
20	Time outside of therapeutic range in atrial fibrillation patients is associated with long-term risk of dementia. Heart Rhythm, 2014, 11, 2206-2213.	0.7	130
21	Parathyroid hormone, vitamin D, renal dysfunction, and cardiovascular disease: Dependent or independent risk factors?. American Heart Journal, 2011, 162, 331-339.e2.	2.7	127
22	Localization of a Gene Responsible for Familial Dilated Cardiomyopathy to Chromosome 1q32. Circulation, 1995, 92, 3387-3389.	1.6	123
23	Improvements in 1-Year Cardiovascular Clinical Outcomes Associated with a Hospital-Based Discharge Medication Program. Annals of Internal Medicine, 2004, 141, 446.	3.9	118
24	Secretory Phospholipase A2-IIA and Cardiovascular Disease. Journal of the American College of Cardiology, 2013, 62, 1966-1976.	2.8	115
25	Impact of Testosterone Replacement Therapy on Myocardial Infarction, Stroke, and Death in Men With Low Testosterone Concentrations in an Integrated Health Care System. American Journal of Cardiology, 2016, 117, 794-799.	1.6	113
26	Usefulness of a Complete Blood Count-Derived Risk Score to Predict Incident Mortality in Patients With Suspected Cardiovascular Disease. American Journal of Cardiology, 2007, 99, 169-174.	1.6	101
27	Short-Term Exposure to Fine Particulate Matter Air Pollution Is Preferentially Associated With the Risk of ST-Segment Elevation Acute Coronary Events. Journal of the American Heart Association, 2015, 4, .	3.7	99
28	Usefulness of Routine Periodic Fasting to Lower Risk of Coronary Artery Disease in Patients Undergoing Coronary Angiography. American Journal of Cardiology, 2008, 102, 814-819.e1.	1.6	82
29	Smartphone ECG for evaluation of STEMI: Results of the ST LEUIS Pilot Study. Journal of Electrocardiology, 2015, 48, 249-259.	0.9	80
30	Lipoprotein-Associated Phospholipase A2: An Independent Predictor of Coronary Artery Disease Events in Primary and Secondary Prevention. American Journal of Cardiology, 2008, 101, S23-S33.	1.6	74
31	The impact of risk score (CHADS2 versus CHA2DS2-VASc) on long-term outcomes after atrial fibrillation ablation. Heart Rhythm, 2015, 12, 681-686.	0.7	72
32	Occurrence of exercise-induced and spontaneous wide complex tachycardia during therapy with flecainide for complex ventricular arrhythmias: A probable proarrhythmic effect. American Heart Journal, 1987, 113, 1071-1077.	2.7	69
33	The Impact of Age on 5-Year Outcomes After Atrial Fibrillation Catheter Ablation. Journal of Cardiovascular Electrophysiology, 2016, 27, 141-146.	1.7	68
34	Genetic variation at the 9p21 locus predicts angiographic coronary artery disease prevalence but not extent and has clinical utility. American Heart Journal, 2008, 156, 1155-1162.e2.	2.7	67
35	Five-Year Outcomes of Catheter Ablation in Patients with Atrial Fibrillation and Left Ventricular Systolic Dysfunction. Journal of Cardiovascular Electrophysiology, 2015, 26, 363-370.	1.7	63
36	Implementation of a computerized cardiovascular information system in a private hospital setting. American Heart Journal, 1998, 136, 792-803.	2.7	53

#	ARTICLE	IF	CITATIONS
37	Which Features of the Metabolic Syndrome Predict the Prevalence and Clinical Outcomes of Angiographic Coronary Artery Disease?. Cardiology, 2004, 101, 185-193.	1.4	53
38	Relation of Routine, Periodic Fasting to Risk of Diabetes Mellitus, and Coronary Artery Disease in Patients Undergoing Coronary Angiography. American Journal of Cardiology, 2012, 109, 1558-1562.	1.6	52
39	Flecainide acetate for paroxysmal supraventricular tachyarrhythmias. American Journal of Cardiology, 1994, 74, 578-584.	1.6	46
40	Clinical Predictors of Risk for Atrial Fibrillation. Mayo Clinic Proceedings, 2014, 89, 1498-1505.	3.0	46
41	Long-Term Natural History of Adult Wolff–Parkinson–White Syndrome Patients Treated With and Without Catheter Ablation. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 1465-1471.	4.8	44
42	Complete blood count risk score and its components, including RDW, are associated with mortality in the JUPITER trial. European Journal of Preventive Cardiology, 2015, 22, 519-526.	1.8	41
43	Limited Evidence for the Health Effects and Safety of Intermittent Fasting Among Patients With Type 2 Diabetes. JAMA - Journal of the American Medical Association, 2020, 324, 341.	7.4	41
44	Percent Time With a Supratherapeutic INR in Atrial Fibrillation Patients Also Using an Antiplatelet Agent Is Associated With Long‐Term Risk of Dementia. Journal of Cardiovascular Electrophysiology, 2015, 26, 1180-1186.	1.7	40
45	Shortened telomere length is associated with paroxysmal atrial fibrillation among cardiovascular patients enrolled in the Intermountain Heart Collaborative Study. Heart Rhythm, 2016, 13, 21-27.	0.7	38
46	Lack of Association of Tegaserod With Adverse Cardiovascular Outcomes in a Matched Case-Control Study. Journal of Cardiovascular Pharmacology and Therapeutics, 2009, 14, 170-175.	2.0	37
47	Effect of folic acid fortification of food on homocysteine-related mortality. American Journal of Medicine, 2004, 116, 158-164.	1.5	36
48	Pilot Study of Novel Intermittent Fasting Effects on Metabolomic and Trimethylamine N-oxide Changes During 24-hour Water-Only Fasting in the FEELGOOD Trial. Nutrients, 2019, 11, 246.	4.1	35
49	Cardiovascular Pharmacogenomics: Current Status, Future Prospects. Journal of Cardiovascular Pharmacology and Therapeutics, 2003, 8, 71-83.	2.0	34
50	World Heart Federation Expert Consensus Statement on Antiplatelet Therapy in East Asian Patients with ACS or Undergoing PCI. Global Heart, 2020, 9, 457.	2.3	34
51	Association of Sociodemographic Factors and Blood Group Type With Risk of COVID-19 in a US Population. JAMA Network Open, 2021, 4, e217429.	5.9	33
52	Joint effects of common genetic variants from multiple genes and pathways on the risk of premature coronary artery disease. American Heart Journal, 2010, 160, 250-256.e3.	2.7	29
53	Failure of benefit and early hazard of bucindolol for Class IV heart failure. Journal of Cardiac Failure, 2003, 9, 266-277.	1.7	26
54	Do Statins Increase the Risk of Idiopathic Polyneuropathy?. American Journal of Cardiology, 2005, 95, 1097-1099.	1.6	26

#	ARTICLE	IF	CITATIONS
55	GlycA and hsCRP are independent and additive predictors of future cardiovascular events among patients undergoing angiography: The intermountain heart collaborative study. American Heart Journal, 2018, 202, 27-32.	2.7	26
56	Multicenter study of the safety and effects of magnetic resonance imaging in patients with coronary sinus left ventricular pacing leads. Heart Rhythm, 2015, 12, 345-349.	0.7	25
57	Atrial Dimensions in Health and Left Ventricular Disease Using Cardiovascular Magnetic Resonance. Journal of Cardiovascular Magnetic Resonance, 2005, 7, 671-675.	3.3	24
58	CHA2DS2-VASc scores and Intermountain Mortality Risk Scores for the joint risk stratification of dementia among patients with atrial fibrillation. Heart Rhythm, 2019, 16, 3-9.	0.7	23
59	Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events. Circulation Genomic and Precision Medicine, 2019, 12, e002471.	3.6	22
60	Feasibility of combining serial smartphone single-lead electrocardiograms for the diagnosis of ST-elevation myocardial infarction. American Heart Journal, 2020, 221, 125-135.	2.7	22
61	Hypothyroidism as a risk factor for statin intolerance. Journal of Clinical Lipidology, 2014, 8, 401-407.	1.5	21
62	Smartphone ECG for evaluation of ST-segment elevation myocardial infarction (STEMI): Design of the ST LEUIS International Multicenter Study. Journal of Electrocardiology, 2018, 51, 260-264.	0.9	21
63	Disposition of Intravenous Pirmenol. Journal of Clinical Pharmacology, 1983, 23, 113-122.	2.0	19
64	Flecainide: A New Prototype Antiarrhythmic Agent. Pharmacotherapy, 1985, 5, 209-221.	2.6	19
65	Evolution of the ACC/AHA Clinical Practice Guidelines inÂPerspective. Journal of the American College of Cardiology, 2015, 65, 2735-2738.	2.8	19
66	Î²-blocker dosage and outcomes after acute coronary syndrome. American Heart Journal, 2017, 184, 26-36.	2.7	19
67	Antibiotic trials for coronary heart disease. Texas Heart Institute Journal, 2004, 31, 33-8.	0.3	19
68	Subsequent Event Risk in Individuals With Established Coronary Heart Disease. Circulation Genomic and Precision Medicine, 2019, 12, e002470.	3.6	17
69	Randomized controlled trial of once-per-week intermittent fasting for health improvement: the WONDERFUL trial. European Heart Journal Open, 2021, 1, .	2.3	17
70	Association of periodic fasting lifestyles with survival and incident major adverse cardiovascular events in patients undergoing cardiac catheterization. European Journal of Preventive Cardiology, 2022, 28, 1774-1781.	1.8	17
71	Association of the dispersion in red blood cell volume with mortality. European Journal of Clinical Investigation, 2015, 45, 541-549.	3.4	16
72	Improving CHA$_2$DS$_2$-VASc stratification of non-fatal stroke and mortality risk using the Intermountain Mortality Risk Score among patients with atrial fibrillation. Open Heart, 2018, 5, e000907.	2.3	16

#	Article	IF	Citations
73	Behavioral Nudges as Patient Decision Support for Medication Adherence: The ENCOURAGE Randomized Controlled Trial. American Heart Journal, 2022, 244, 125-134.	2.7	16
74	Coronary Artery Calcium Versus Pooled Cohort Equations Score for Primary Prevention Guidance. JACC: Cardiovascular Imaging, 2022, 15, 843-855.	5.3	15
75	Impact of the Food and Drug Administration Approval of Flecainide and Encainide on Coronary Artery Disease Mortality: Putting Deadly Medicine to the Test. American Journal of Cardiology, 1997, 79, 43-47.	1.6	14
76	Validation and Quantification of Genetic Determinants of Lipoprotein-a Levels and Predictive Value for Angiographic Coronary Artery Disease. American Journal of Cardiology, 2013, 112, 799-804.	1.6	14
77	Real world MRI experience with nonconditional and conditional cardiac rhythm devices after MagnaSafe. Journal of Cardiovascular Electrophysiology, 2017, 28, 1468-1474.	1.7	14
78	Contemporary Clinical Trials in Ventricular Tachycardia and Fibrillation: Implications of ESVEM, CASCADE, and CASH for Clinical Management. Journal of Cardiovascular Electrophysiology, 1995, 6, 880-886.	1.7	13
79	Free thyroxine within the normal reference range predicts risk of atrial fibrillation. Journal of Cardiovascular Electrophysiology, 2020, 31, 18-29.	1.7	12
80	Absence of Coronary Artery Calcium During Positron Emission Tomography Stress Testing in Patients Without Known Coronary Artery Disease Identifies Individuals With Very Low Risk of Cardiac Events. Circulation: Cardiovascular Imaging, 2020, 13, e009907.	2.6	12
81	Implementation of a cardiac PET stress program: comparison of outcomes to the preceding SPECT era. JCI Insight, 2018, 3, .	5.0	12
82	Circulating Levels of Biomarkers of Cerebral Injury in Patients with Atrial Fibrillation. American Journal of Cardiology, 2019, 124, 1697-1700.	1.6	11
83	Economics and outcomes of sotalol inâ€patient dosing approaches in patients with atrial fibrillation. Journal of Cardiovascular Electrophysiology, 2022, 33, 333-342.	1.7	11
84	Pulmonary-Specific Intermountain Risk Score Predicts All-Cause Mortality via Spirometry, the Red Cell Distribution Width, and Other Laboratory Parameters. Respiratory Care, 2015, 60, 1314-1323.	1.6	10
85	Extreme erythrocyte macrocytic and microcytic percentages are highly predictive of morbidity and mortality. JCI Insight, 2018, 3, .	5.0	10
86	Effect of Low-Intensity vs Standard-Intensity Warfarin Prophylaxis on Venous Thromboembolism or Death Among Patients Undergoing Hip or Knee Arthroplasty. JAMA - Journal of the American Medical Association, 2019, 322, 834.	7.4	9
87	Comparison of Three Atherosclerotic Cardiovascular Disease Risk Scores With and Without Coronary Calcium for Predicting Revascularization and Major Adverse Coronary Events in Symptomatic Patients Undergoing Positron Emission Tomography-Stress Testing. American Journal of Cardiology, 2020, 125, 341-348.	1.6	9
88	SARS-CoV-2 as an inflammatory cardiovascular disease: current knowledge and future challenges. Future Cardiology, 2021, 17, 1277-1291.	1.2	9
89	Comparison of Signal-Averaging Electrocardiographic Systems Using Device Specific Criteria in 104 Normal Subjects. PACE - Pacing and Clinical Electrophysiology, 1994, 17, 2178-2182.	1.2	8
90	Utility of high density lipoprotein particle concentration in predicting future major adverse cardiovascular events among patients undergoing angiography. Clinical Biochemistry, 2016, 49, 1122-1126.	1.9	8

#	Article	IF	Citations
91	Temporal changes in statin prescription and intensity at discharge and impact on outcomes in patients with newly diagnosed atherosclerotic cardiovascular disease—Real-world experience within a large integrated health care system: The IMPRES study. Journal of Clinical Lipidology, 2018, 12, 1008-1018.e1.	1.5	8
92	Discovery of TITIN Gene Truncating Variant Mutations and 5-Year Outcomes in Patients With Nonischemic Dilated Cardiomyopathy. American Journal of Cardiology, 2020, 137, 97-102.	1.6	8
93	Intermittent fasting and changes in Galectin-3: A secondary analysis of a randomized controlled trial of disease-free subjects. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 1538-1548.	2.6	8
94	Association of periodic fasting with lower severity of COVID-19 outcomes in the SARS-CoV-2 prevaccine era: an observational cohort from the INSPIRE registry. BMJ Nutrition, Prevention and Health, 2022, 5, 145-153.	3.7	8
95	Prediction of Long-Term Incidence of Chronic Cardiovascular and Cardiopulmonary Diseases in Primary Care Patients for Population Health Monitoring: The Intermountain Chronic Disease Model (ICHRON). Mayo Clinic Proceedings, 2019, 94, 1221-1230.	3.0	7
96	The association of antidepressant and statin use with death and incident cardiovascular disease varies by depression severity. Psychology, Health and Medicine, 2017, 22, 919-931.	2.4	6
97	Spectrum of radionuclide perfusion study abnormalities in takotsubo cardiomyopathy. Journal of Nuclear Cardiology, 2022, 29, 1034-1046.	2.1	6
98	Reperfusion in Acute Myocardial Infarction. Drugs, 1987, 33, 154-162.	10.9	5
99	Worsening of Ventricular Tachycardia by Amiodarone. Journal of Clinical Pharmacology, 1988, 28, 406-411.	2.0	5
100	Letter by Horne et al Regarding Article, "Prognostic Value of Fasting Versus Nonfasting Low-Density Lipoprotein Cholesterol Levels on Long-Term Mortality: Insight From the National Health and Nutrition Survey III (NHANES-III)". Circulation, 2015, 131, e472.	1.6	5
101	Depression as a Driving Force for Low Time in Therapeutic Range and Dementia in Patients With and Without Atrial Fibrillation. American Journal of Cardiology, 2021, 153, 58-64.	1.6	5
102	Association of Rhesus Factor Blood Type with Risk of SARS‐CoV‐2 Infection and COVID‐19 Severity. British Journal of Haematology, 2022, , .	2.5	5
103	The Disposition of Recainam Hydrochloride During and After Intravenous Loading and Maintenance Infusion in Cardiac Patients. Journal of Clinical Pharmacology, 1987, 27, 951-956.	2.0	4
104	The utility of the apolipoprotein A1 remnant ratio in predicting incidence coronary heart disease in a primary prevention cohort: The Jackson Heart Study. European Journal of Preventive Cardiology, 2016, 23, 769-776.	1.8	4
105	Improving secondary cardiovascular risk prediction: taking a few steps along the long path from probability toward certainty. European Heart Journal, 2017, 38, 3219-3221.	2.2	4
106	Evaluation of TReatment With Angiotensin Converting Enzyme Inhibitors and the Risk of Lung Cancer: ERACER—An Observational Cohort Study. Journal of Cardiovascular Pharmacology and Therapeutics, 2021, 26, 321-327.	2.0	4
107	A Small but Significantly Greater Incidence of Inflammatory Heart Disease Identified After Vaccination for Severe Acute Respiratory Syndrome Coronavirus 2. Open Forum Infectious Diseases, 2022, 9, ofab663.	0.9	4
108	Pharmacogenomics in Cardiovascular Medicine. Drug Development Research, 2004, 62, 180-190.	2.9	3

#	Article	IF	Citations
109	Preferential Metabolic Improvement by Intermittent Fasting in People with Elevated Baseline Red Cell Distribution Width: A Secondary Analysis of the WONDERFUL Randomized Controlled Trial. Nutrients, 2021, 13, 4407.	4.1	3
110	Recent Clinical Developments in Thrombolysis in Acute Myocardial Infarction. Drugs, 1987, 33, 22-32.	10.9	2
111	Effect of Genetic Variants, Especially CYP2C9 and VKORC1, on the Pharmacology of Warfarin. Seminars in Thrombosis and Hemostasis, 2013, 39, 112-112.	2.7	2
112	Safety and Efficacy of Periprocedural Heparin Plus a Short-Term Infusion of Tirofiban Versus Bivalirudin Monotherapy in Patients Who Underwent Percutaneous Coronary Intervention (from the) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 1927-1934.	1.6	2
113	Smartphone 12-lead ECG—Exciting but must be handled with care. American Heart Journal, 2020, 226, 269.	2.7	2
114	Intermountain chronic disease risk score (ICHRON) validation for prediction of incident chronic disease diagnoses in an australian primary prevention population. European Journal of Internal Medicine, 2020, 79, 81-87.	2.2	2
115	Simplifying the ISCHEMIA trial algorithm for clinical practice: Identifying left main coronary artery disease using coronary artery calcium scans. American Heart Journal, 2021, 239, 129-134.	2.7	2
116	The Total Artificial Heart: From Initial Application to Therapeutic Option. Journal of Interventional Cardiology, 1997, 10, 335-342.	1.2	1
117	Fasting and Other Health Influences. American Journal of Cardiology, 2009, 103, 1042.	1.6	1
118	Haptoglobin 2-2 Genotyping for Refining Standard Cardiovascular Risk Assessment. Journal of the American College of Cardiology, 2015, 66, 1800-1802.	2.8	1
119	Circulating Thyroxine. Circulation Research, 2017, 121, 1304-1306.	4.5	1
120	Association of the Intermountain Risk Score with major adverse health events in patients positive for COVID-19: an observational evaluation of a US cohort. BMJ Open, 2022, 12, e053864.	1.9	1
121	Therapeutic management of acute myocardial infarction. American Journal of Health-System Pharmacy, 1990, 47, S5-S10.	1.0	0
122	Clinical Implications of the CAMIAT, EMIAT and SWORD Trials: A North American Perspective. Journal of Interventional Cardiac Electrophysiology, 1998, 2, 30-33.	1.0	0
123	Spontaneous Variability of Ventricular Ectopic Activity in Patients with Sustained Ventricular Tachycardia and in Survivors of Cardiac Arrest. Annals of Noninvasive Electrocardiology, 1998, 3, 194-201.	1.1	0
124	Introduction: NASPE Atrial Fibrillation Supplement 2004. Journal of Interventional Cardiac Electrophysiology, 2004, 10, 5-7.	1.3	0
125	Practical laboratory-based clinical decision tools and associations with short-term bleeding and mortality outcomes. Clinica Chimica Acta, 2018, 482, 166-171.	1.1	0
126	Absent or Mild Coronary Calcium Predicts Low-Risk Stress Test Results and Outcomes in Patients Considered for Flecainide Therapy. Journal of Cardiovascular Pharmacology and Therapeutics, 2021, 26, 648-655.	2.0	0

#	ARTICLE	IF	CITATIONS
127	The TEAM Studies: A Review. Journal of Interventional Cardiology, 1996, 9, 361-372.	1.2	0
128	Abstract 13551: Identifying Left Main Coronary Artery Disease Using Coronary Artery Calcium Scans. Circulation, 2020, 142, .	1.6	0
129	Abstract 14607: Randomized Controlled Trial of Once-Per-Week Intermittent Fasting for the Reduction of Low-Density Lipoprotein Cholesterol. Circulation, 2020, 142, .	1.6	0
130	Abstract 16802: Economics and Outcomes of Sotalol and Dofetilide In-Patient Dosing Approaches in Patients With Atrial Fibrillation. Circulation, 2020, 142, .	1.6	0
131	Abstract 13889: The Influence of Depression on Dementia Risk in Patients With Atrial Fibrillation. Circulation, 2020, 142, .	1.6	0
132	Patterns of cardiac dysfunction after carbon monoxide poisoning. Undersea and Hyperbaric Medicine, 2020, 47, 477-485.	0.3	0